BRISTOL-MEYERS SQUIBB PHARMACEUTICAL GROUP -- PROHANCE FOR INJECTION -- 6505-01-371-4206

Product ID: PROHANCE FOR INJECTION MSDS Date:01/20/1994 FSC:6505 NIIN:01-371-4206 Status Code:A MSDS Number: CKLJG === Responsible Party === Company Name: BRISTOL-MEYERS SQUIBB PHARMACEUTICAL GROUP Box:191 City:NEW BRUNSWICK State:NJ ZIP:08903 Country:US Info Phone Num: 908-519-3843 Emergency Phone Num:908-519-3843 Chemtrec Ind/Phone: (800) 424-9300 CAGE:TO591 === Contractor Identification === Company Name: BRISTOL-MEYERS SQUIBB PHARMACEUTICAL GROUP Box:191 City:NEW BRUNSWICK State:NJ ZIP:08903 Country:US Phone:908-519-3843 CAGE: TO591 Ingred Name: GADOTERIDOL CAS:120066-54-8 = Wt:24.Ingred Name:WATER CAS:7732-18-5 RTECS #:2C0110000 Ingred Name: TROMETHAMINE CAS:77-86-1 RTECS #:TY2900000 < Wt:1. Ingred Name:CALTERIDOL CALCIUM CAS:121915-83-1 < Wt:1. LD50 LC50 Mixture:LD50 (RAT) > 5,880 MG/KG Routes of Entry: Inhalation:NO Skin:NO Ingestion:NO

Reports of Carcinogenicity:NTP:NO IARC:NO OSHA:NO Health Hazards Acute and Chronic:UNDER NORMAL CONDITIONS, THIS PRODUCT IS CONTAINED WITHIN VIALS AND SKIN/EYE CONTACT OR INHALATION WOULD NOT BE EXPECTED. PROHANCE FOR INJECTION CONTAINS GADOTERIDOL, A CONTRAST AGENT IN MAGNETIC RES ONANCE IMAGING (MRI) INTENDED FOR INTRAVENOUS INJECTION, UNDER THE CARE OF A PHYSICIAN. WHEN ADMINISTERED PROPERLY, THIS PRODUCT CAN BE USED TO VISUALIZE SUBTLE BRAIN LESIONS. NAUSEA AND TASTE CHANGES WERE REPORTED IN 1.4% OF PATIENTS RECEIVING THIS INJECTION. ADVERSE CARDIOVASCULAR, DIGESTIVE, NERVOUS SYSTEM, RESPIRATORY, DERMAL AND AUDITORY EFFECTS WERE EXPERIENCED BY LESS THAN 1% OF PATIENTS.

Explanation of Carcinogenicity:NONE KNOWN. Effects of Overexposure:NO INFORMATION. Medical Cond Aggravated by Exposure:N/P.

First Aid:INGEST: SEEK MEDICAL ATTENTION IMMEDIATELY. INDUCTION OF VOMITING SHOULD BE CONSIDERED FOR SIGNIFICANT INGESTION IF PERSON IS CONSCIOUS AND NOT EXPERIENCING CONVULSIONS. NEVER GIVE ANYTHING BY MOUTH T O AN UNCONSCIOUS PERSON. INHALE: REMOVE TO FRESH AIR. IF PERSON IS NOT BREATHING GIVE ARTIFICIAL RESPIRATION. IF BREATHING IS DIFFICULT ADMINISTER OXYGEN. SKIN: WASH WITH SOAP AND WATER. GET MEDICAL A TTENTION IF IRRITATION DEVELOPS AND PERSISTS. EYE: HOLD EYELIDS APART AND FLUSH WITH RUNNING WATER FOR AT LEAST 15 MINUTES. GET MEDICAL ATTENTION IMMEDIATELY.

- Extinguishing Media:UNLIKELY TO BURN IN VIAL. IN CASE OF FIRE, FLOOD WITH WATER.
- Fire Fighting Procedures:FIREFIGHTERS SHOULD WEAR SELF-CONTAINED BREATHING APPARATUS, FLAME AND CHEMICAL RESISTANT CLOTHING, BOOTS AND GLOVES. EVACUATE WITH WATER FROM A MAXIMUM DISTANCE. Unusual Fire/Explosion Hazard:NONE KNOWN.

Spill Release Procedures:ABSORB SPILL WITH INERT MATERIAL, E.G., SAND, VERMICULITE OR OTHER NON-COMBUSTIBLE ABSORBENT MATERIALS, AND PLACE INTO A CLOSED CONTAINER FOR RECLAMATION OR DISPOSAL. FLUSH RESIDUAL SPILL AREA WITH W ATER TO PROCESS SEWER IF ALLOWABLE UNDER NATIONAL, STATE, OR LOCAL PERMITS OR REGULATIONS.

Handling and Storage Precautions:DO NOT BREAK VIALS. AVOID SKIN AND EYE CONTACT. SHOULD BE STORED AT CONTROLLED ROOM TEMPERATURES (15 - 30 DEGREE C). DO NOT FREEZE.

======= Exposure Controls/Personal Protection ==========

Respiratory Protection:WHEN ENGINEERING CONTROLS ARE NOT SUFFICIENT TO CONTROL EXPOSURE, WEAR APPROVED RESPIRATORY PROTECTION APPROPRIATE FOR EXPOSURE POTENTIAL; SELF-CONTAINED BREATHING APPARATUS SHOULD BE AVAILABLE FOR EM ERGENCY USE. Ventilation: NONE BEYOND GOOD ROOM VENTILATION NORMALLY REQUIRED. Protective Gloves: IMPERVIOUS GLOVES. Eye Protection: SAFETY GLASSES. Other Protective Equipment:WEAR PROTECTIVE OVERALLS WHENEVER THE POTENTIAL FOR SEVERE DUSTY CONDITIONS OR SPLASHING AND SPRAYING LIQUIDS EXISTS. Work Hygienic Practices:WASH HANDS AFTER HANDLING COMPOUNDS AND BEFORE EATING, SMOKING, USING LAVATORY, AND AT THE END OF THE DAY. Supplemental Safety and Health HCC:N1 Boiling Pt:=100.C, 212.F Melt/Freeze Pt:=0.C, 32.F Spec Gravity:1.14 Evaporation Rate & Reference:SAME AS WATER Solubility in Water: ABOUT 620 MG/ML Appearance and Odor: CLEAR, COLORLESS TO SLIGHTLY YELLOW AQUEOUS LIQUID WHICK IS PACKAGED IN VIALS. Stability Indicator/Materials to Avoid:YES ACIDS. Stability Condition to Avoid: WHEN STORED AT CONTROLLED ROOM TEMPERATURES (15-30 DEGREE C) IN ORIGINAL CONTAINER, MATERIAL IS STABLE TO EXPIRATION DATE SHOWN ON PRODUCT LABEL. Hazardous Decomposition Products:OXIDES OF CARBON, AND OXIDES OF NITROGEN. Toxicological Information: IN LABORATORY ANIMALS, GADOTERIDOL WAS ESSENTIALLY NONTOXIC WHEN ADMINISTERED BY THE INTRAVENOUS ROUTE. AT DOSES, APPROXIMATELY 100 TIMES GREATER THAN THE CLINICAL DOSE, EXPERIMENTAL ANIMALS EXHIBITED ATAXIA, CONVULSIONS, COLLAPSE, IRREGULAR RESPIRATION. NO TREATMENT-RELATED PATHOLOGIC CHANGES WERE SEEN IN SURVIVING ANIMALS. Ecological:DAPHNIA ACUTE TOXICITY (EC50) > 920 MG/L. CHEMICAL FATE INFORMATION: HALF-LIFE 9HYDROLYSIS): < 10% HYDROLYSIS AFTER 5 DAYS AT 50 DEGREES C AT ALL PH LEVELS TESTED; CONSIDERED HYDROLYTICALLY STABLE. AE ROBIC BIODEGRADATION: HALF-LIFE DETERMINED TO BE GREATER THAN 28 DAYS. Waste Disposal Methods: DISPOSE OF IN ACCORDANCE WITH NATIONAL, STATE, LOCAL OR APPLICABLE COUNTRY REGULATIONS. Transport Information:DOT: NOT REGULATED.

SARA Title III Information:NONE NOTES Federal Regulatory Information:NONE NOTED

Disclaimer (provided with this information by the compiling agencies): This information is formulated for use by elements of the Department of Defense. The United States of America in no manner whatsoever, expressly or implied, warrants this information to be accurate and disclaims all liability for its use. Any person utilizing this document should seek competent professional advice to verify and assume responsibility for the suitability of this information to their particular situation.